Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had reached a key milestone toward monetizing its unique approach to leverage AI in oncology drug discovery. The company noted that earlier this year its proprietary Discovery 21 proof-of-concept campaign showed the ability of its Patient-Centric Discovery by Active Learning (“PeDAL”) platform to make high-confidence predictions of drug response on ovarian tumors samples. Those results have been validated, according to POAI’s most recent announcement, which stated that PeDAL accurately and reproducibly predicted drug response results. According to the announcement, Discovery 21 tested PeDAL’s ability to make drug response predictions with an experimental space of 175 FDA-approved cancer drugs and tumor samples from 130 ovarian cancers. The PeDAL platform is powered by machine learning that drives experimental testing to assess models of hundreds of diverse tumor samples against hundreds of drug compounds for early-stage drug discovery. “These results demonstrate that PeDAL works with real-world drug compounds and tumor samples,” said Predictive Oncology CEO and chair J. Melville (Mel) Engle in the press release. “We expect that pharma will be keen to use this technology, which increases the probability of technical success and lowers both the cost and time of bringing new drugs to market. This in turn will bring us closer to our overall mission of determining optimal therapies for the treatment of cancer.”
To view the full press release, visit https://ibn.fm/l3AEQ
About Predictive Oncology Inc.
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcomes. Using artificial intelligence, Predictive Oncology uses a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to determine optimal therapies to be used to ultimately eliminate cancer. As the drug-discovery community has now realized, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics. Predictive Oncology instead takes a multiomic approach, which considers the vast multitude of factors that make each cancer unique.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
